Moderna, Inc. (MRNA) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
MRNA Insider Trading Activity
MRNA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $6,008,569 | 2 | 5 |
Sells | $60,631,414 | 42 | 95 |
Related Transactions
| Bancel Stephane | Chief Executive Officer | 1 | $5M | 0 | $0 | $5M |
| SAGAN PAUL | director | 1 | $1M | 0 | $0 | $1M |
| Mock James M | Chief Financial Officer | 0 | $0 | 8 | $531,697 | $-531,697 |
| Klinger Shannon Thyme | Chief Legal Officer | 0 | $0 | 11 | $1.28M | $-1.28M |
| Hoge Stephen | President | 0 | $0 | 11 | $6.01M | $-6.01M |
| AFEYAN NOUBAR | director | 0 | $0 | 12 | $52.82M | $-52.82M |
About Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Moderna, Inc.
Over the last 12 months, insiders at Moderna, Inc. have bought $6.01M and sold $60.63M worth of Moderna, Inc. stock.
On average, over the past 5 years, insiders at Moderna, Inc. have bought $6.01M and sold $712.52M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bancel Stephane (Chief Executive Officer) — $5M. SAGAN PAUL (director) — $1M.
The last purchase of 31,620 shares for transaction amount of $1M was made by SAGAN PAUL (director) on 2025‑03‑03.
List of Insider Buy and Sell Transactions, Moderna, Inc.
| 2025-03-03 | Bancel Stephane | Chief Executive Officer | 160,314 0.0429% | $31.22 | $5M | -9.28% | ||
| 2025-03-03 | SAGAN PAUL | director | 31,620 0.0086% | $31.76 | $1M | -9.28% | ||
| 2024-12-09 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 529 0.0001% | $44.68 | $23,637 | -26.05% | |
| 2024-12-03 | Sale | Hoge Stephen | President | 314 <0.0001% | $43.30 | $13,595 | -20.55% | |
| 2024-12-03 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 112 <0.0001% | $43.30 | $4,849 | -20.55% | |
| 2024-11-29 | Sale | Hoge Stephen | President | 291 <0.0001% | $42.79 | $12,452 | -21.33% | |
| 2024-11-29 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 1,418 0.0004% | $42.79 | $60,675 | -21.33% | |
| 2024-11-29 | Sale | Mock James M | Chief Financial Officer | 1,420 0.0004% | $42.79 | $60,761 | -21.33% | |
| 2024-11-11 | Sale | Hoge Stephen | President | 277 <0.0001% | $46.10 | $12,771 | -19.39% | |
| 2024-10-07 | Sale | Mock James M | Chief Financial Officer | 715 0.0003% | $60.12 | $42,986 | -38.81% | |
| 2024-09-09 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 551 0.0002% | $73.57 | $40,539 | -48.56% | |
| 2024-09-03 | Sale | Hoge Stephen | President | 318 0.0001% | $76.99 | $24,483 | -45.80% | |
| 2024-09-03 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 114 <0.0001% | $76.99 | $8,777 | -45.80% | |
| 2024-08-29 | Sale | Hoge Stephen | President | 300 0.0001% | $78.03 | $23,408 | -48.99% | |
| 2024-08-29 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 162 <0.0001% | $78.03 | $12,640 | -48.99% | |
| 2024-08-29 | Sale | Mock James M | Chief Financial Officer | 162 <0.0001% | $78.03 | $12,640 | -48.99% | |
| 2024-08-28 | Sale | Klinger Shannon Thyme | Chief Legal Officer | 1,319 0.0006% | $79.39 | $104,722 | -49.48% | |
| 2024-08-28 | Sale | Mock James M | Chief Financial Officer | 1,321 0.0006% | $79.39 | $104,881 | -49.48% | |
| 2024-08-12 | Sale | Hoge Stephen | President | 254 0.0001% | $84.10 | $21,363 | -49.86% | |
| 2024-07-31 | Sale | AFEYAN NOUBAR | director | 15,000 0.0109% | $119.96 | $1.8M | -65.18% |
Insider Historical Profitability
| Bancel Stephane | Chief Executive Officer | 9210686 2.3816% | $221.24M | 1 | 416 | |
| AFEYAN NOUBAR | director | 2224015 0.5751% | $53.42M | 0 | 89 | |
| Hoge Stephen | President | 1443904 0.3734% | $34.68M | 0 | 185 | |
| SAGAN PAUL | director | 312027 0.0807% | $7.49M | 2 | 1 | +262.16% |
| Klinger Shannon Thyme | Chief Legal Officer | 20446 0.0053% | $491,112.92 | 0 | 25 | |
| Mock James M | Chief Financial Officer | 11066 0.0029% | $265,805.32 | 0 | 12 | |
| Trieu Vuong | Chairman of the Board | 11117141 2.8746% | $267.03M | 2 | 0 | |
| Flagship Ventures Fund IV General Partner LLC | 6420766 1.6602% | $154.23M | 0 | 5 | ||
| Novartis Bioventures Ltd | 10 percent owner | 2495065 0.6451% | $59.93M | 0 | 6 | |
| Pryor Cashman LLP | 10 percent owner | 1591959 0.4116% | $38.24M | 0 | 5 | |
| Kim Lorence H. | Chief Financial Officer | 1202510 0.3109% | $28.88M | 0 | 15 | |
| Ramelli Joseph W. | Chief Executive Officer | 440653 0.1139% | $10.58M | 4 | 0 | |
| Duffy Timothy M | Chief Business Officer | 56395 0.0146% | $1.35M | 0 | 1 | |
| Costantino Henry R | CSO - Delivery | 24485 0.0063% | $588,129.70 | 0 | 3 | |
| KANIA EDWIN M JR | 10 percent owner | 23847 0.0062% | $572,804.94 | 0 | 3 | |
| Nader Francois | 20607 0.0053% | $494,980.14 | 0 | 1 | ||
| Andres Juan | See remarks | 12803 0.0033% | $307,528.06 | 0 | 171 | |
| FRENCH J MICHAEL | CEO | 10000 0.0026% | $240,200.00 | 1 | 0 | |
| LEE JENNIFER LING | Chief Accounting Officer | 4419 0.0011% | $106,144.38 | 0 | 1 | |
| HUTT PETER BARTON | director | 3924 0.001% | $94,254.48 | 0 | 2 | |
| Garay Arpa | Chief Commercial Officer | 3690 0.001% | $88,633.80 | 0 | 3 | |
| Meline David W | Chief Financial Officer | 2857 0.0007% | $68,625.14 | 0 | 3 | |
| HENDERSON LORI M. | General Counsel and Secretary | 901 0.0002% | $21,642.02 | 0 | 29 | |
| Burton Paul | Chief Medical Officer | 954 0.0002% | $22,915.08 | 0 | 2 | |
| NABEL ELIZABETH G | director | 0 0% | $0 | 0 | 2 | |
| Zaks Tal Zvi | Chief Medical Officer | 0 0% | $0 | 0 | 72 |
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $11.84B | |
$159,914,414 | 243 | 18.52% | $7.51B | |
$211,610,344 | 91 | 38.45% | $6.28B | |
$2,765,836 | 72 | 20.00% | $11.26B | |
$108,876,545 | 67 | 72.81% | $5.9B | |
$2,449,191,716 | 58 | 16.50% | $60.65B | |
$11,789,714 | 49 | 14.35% | $11.95B | |
$323,520,369 | 46 | 31.46% | $34.89B | |
$88,307,390 | 38 | -1.70% | $6.57B | |
$13,655,378 | 35 | 17.13% | $13.52B | |
$10,499,766 | 34 | 70.55% | $12.3B | |
$415,105,240 | 19 | -14.04% | $6.39B | |
$83,065,496 | 16 | 9.40% | $7.35B | |
$152,272,932 | 16 | -10.78% | $18.16B | |
$627,701,115 | 15 | 145.68% | $16.78B | |
$948,235 | 8 | 15.55% | $7.5B | |
$4,849,105 | 4 | 2.71% | $6.3B | |
$40,276,273 | 4 | 34.57% | $7.61B | |
Moderna, Inc. (MRNA) | $999,989 | 1 | 262.16% | $9.29B |
MRNA Institutional Investors: Active Positions
| Increased Positions | 383 | +47.11% | 37M | +14.4% |
| Decreased Positions | 339 | -41.7% | 26M | -10.38% |
| New Positions | 123 | New | 9M | New |
| Sold Out Positions | 124 | Sold Out | 2M | Sold Out |
| Total Postitions | 857 | +5.41% | 265M | +4.02% |
MRNA Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $1.11M | 10.42% | 40.32M | +97,536 | +0.24% | 2024-12-31 |
| Baillie Gifford & Co | $1.07M | 10.05% | 38.89M | -4M | -8.4% | 2024-12-31 |
| Blackrock, Inc. | $750,472.00 | 7.02% | 27.18M | +1M | +5.39% | 2025-03-31 |
| Fmr Llc | $515,331.00 | 4.82% | 18.66M | +1M | +7.38% | 2024-12-31 |
| State Street Corp | $485,307.00 | 4.54% | 17.58M | +730,024 | +4.33% | 2024-12-31 |
| Theleme Partners Llp | $201,742.00 | 1.89% | 7.31M | +80,000 | +1.11% | 2024-12-31 |
| Geode Capital Management, Llc | $199,934.00 | 1.87% | 7.24M | +171,774 | +2.43% | 2024-12-31 |
| Ubs Group Ag | $140,076.00 | 1.31% | 5.07M | +3M | +123.58% | 2024-12-31 |
| Invesco Ltd. | $138,228.00 | 1.29% | 5.01M | +979,858 | +24.34% | 2024-12-31 |
| Flagship Pioneering Inc. | $127,894.00 | 1.2% | 4.63M | 0 | 0% | 2024-12-31 |